NICO Clinical Evidence

Improve health

Lower costs

Better care

Triple aim of healthcare

Evidence is mounting

50,000+
Patient lives impacted

35+
Presentations at national and international Neurosurgical conferences

250+
Peer-reviewed publications and abstracts

These independent publications show:
Improved safety, efficiency and reduced surgical morbidity associated with the MIPS technique while using NICO technologies.¹

Evidence also suggests MIPS supported by BrainPath provides economic value for the hospital when analyzing the entire episode of care.⁴This, combined with a reduction in the ICU length of stay, helps improve the patient experience of care and supports healthcare’s commitment to achieving the Triple Aim.

ICH evacuation clinical impact

Clinical Advantages
Using a repeatable approach (trans-sulcal, parafascicular) and technology (BrainPath for access and NICO Myriad NOVUS to mechanically evacuate the clot) provides three clinical advantages for ICH evacuation:

Intervention in an acute time period without clot stability²
Effective hemostasis management using a bi-manual technique²
Consistent evacuation >90% of clot^2,3,4,5

Selected clinical outcomes

98.2% median clot evacuation²
mRS <3 in 63% of patients³
<15mL EOT volumes in 94 of 98 patients studied^2,3,4,5
Statistically significant post-op GCS improvement^2,4
Mortality Improvement (vs pre-op ICH score)^2,4
Decrease in ICU length of stay from 12 to 4 days⁶

Selected economic outcomes

Increased surgical options for patients vs medical management.¹
Reduction in repetitive non-contrast CT scans.⁴
Throughput
- 55% decrease in mechanical ventilation days.⁴
- 18% decrease in neuro-ICULOS days, freeing-up neuro-ICU beds.⁴
- 47% decrease in cost per patient.⁴

Pre-Op

Post-Op

Tumor and brain biopsy clinical impact

In a 2020 Meta-Analysis published in World Neurosurgery⁸that included 29 publications meeting rigorous inclusion criteria, more than 280 patients were included in a review of current studies on use of MIPS with BrainPath. The outcomes not only confirmed the success of non-disruptive, trans-sulcal access and the ability to achieve microsurgical techniques and hemostasis management, but also the following:

Selected clinical outcomes

Lower surgical morbidity / post-operative complications (8.3%) as compared to traditional craniotomy⁷
80.6% of cases achieved gross total resection⁷
100% gross total resection for colloid cyst⁷
100% success in achieving pathologic diagnosis for all biopsy cases⁷

Selected clinical outcomes

Several cohorts have reported shorter length of hospital stay with MIPS using BrainPath as compared to traditional craniotomy, with benefits of:
- Minimal wound disruption⁷
- Decreased risk of post-operative wound infection⁷
- Lower post-operative complications⁷

Pre-Op

Post-Op

Pre-Op MR-DTI

Post-Op MR-DTI

Economic impact

Clinical paper shows substantial economic benefit to hospital.

Greater than 50% average reduction in ICU length of stay⁶
Average economic benefit to the hospital of $12,000 per patient for 28 patients⁶
Net estimated benefit to the bottom line of $329,659⁵

Economic benefit of BrainPath surgery* for appropriate patients

$329,659

Economic return
*refer to Table 5 in published paper

54% reduced LOS

Cost
*

Contact Us

To learn more about Stryker products or our other offerings to help advance neurosurgery and transform lives, please complete the form below.

Thank you!

Triple aim of healthcare

Evidence is mounting